Navigation Links
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer

d survival, as well as the occurrence of adverse events and induction of immune response.

An earlier Phase 1 trial of GVAX immunotherapy for pancreatic cancer was conducted by the Johns Hopkins Sidney Kimmel Cancer Center in 14 patients who also received the immunotherapy following surgical resection of their tumor and standard adjuvant radiation and chemotherapy. As first reported in the Journal of Clinical Oncology in January 2001, three of eight patients who received the therapeutic dose levels of the immunotherapy had prolonged disease-free survival for a period of at least eight years. This outcome is considered particularly significant since all three long-term survivors were judged to be at high risk for recurrent cancer due to microscopic evidence of residual pancreatic tumor following surgery and two patients had metastatic tumor in regional lymph nodes. In addition, the three patients with prolonged disease-free survival -- but not the five who progressed and died -- showed evidence of treatment-associated antitumor immunity, including induction of T cell responses to the candidate tumor-associated antigen, mesothelin.

Pancreatic cancer is the fourth leading cause of cancer death in the United States. According to the American Cancer Society, approximately 37,170 Americans will be diagnosed with pancreatic cancer in 2007, and 33,370 are expected to die from the disease in 2007. Because symptoms are non-specific, cancer of the pancreas is rarely diagnosed at an early stage leaving surgical removal of the tumor as a treatment option for only approximately 20 to 30 percent of pancreatic cancer patients. The median survival of patients with operable cancer of the pancreas with currently available therapies is approximately 17 to 22 months.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM)
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... Care Conference in Boston.   The live presentation ... Time / 8:20 a.m. Pacific Time.  The presentation will be ... http://www.neurocrine.com . If you are unable ...
(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering.  In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering.   A ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... Pharmasset, Inc.,(Nasdaq: VRUS ) has commenced ... in,combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) ... hepatitis C,virus (HCV) genotype 1. R7128 is a ... inhibitor of HCV that is being developed,through Pharmasset,s ...
... EDMONTON, Alberta, Oct. 2 Medical Services,International Inc. (Pink ... its VScan Dengue Fever Kit is increasing. Dengue Fever ... of the worst,outbreaks in decades causing agonizing joint pain ... so far this year. This year so far ...
Cached Medicine Technology:Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 2Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 3Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 4Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C 5Demand for VScan Dengue Fever Test Kits Increases 2
(Date:5/25/2013)... On May 25, Voices Against Brain Cancer, ... comments on a new study by the Max Planck ... plasma into brain cancer treatment may help when dealing ... Science Daily article, physicists from the Max Planck ... the “synergistic effect of cold atmospheric plasma -- a ...
(Date:5/25/2013)... May 25, 2013 Dr. Farooq Ashraf, ... clinic in Dubai, has announced his practice’s adoption of ... the only FDA-cleared femtosecond laser proven with more than ... and precision of LASIK. , “We are happy to ... Femtosecond Laser at our Dubai LASIK practice,” Ashraf said ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The Slim Weight ... effectiveness and results. This is due to the highly sought ... patches. Slim weight patch offers an extra 2 months supply ... fitness goals and get the body you desire faster than ... Official Website , With Slim weight patch consumers can ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 For ... than finals week. Increasingly, they are turning to ... awake and study. For more on this, go ... drug treatment facility, warns that students who pick ... are at risk for developing a physical and ...
(Date:5/25/2013)... Richmond, Virginia (PRWEB) May 25, 2013 ... bracelet that relieves pain in seconds for arthritis, tendinitis ... innovator in alternative pain relief products announced a ... seconds. The magnetic bracelet for pain relief is demonstrated ... for pain uses 5400 Gauss magnets and has customers ...
Breaking Medicine News(10 mins):Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2
... to relieve stress, a common cause of heart ... ... us think,of love and Valentine,s Day. This February, which also is National Heart,Awareness ... your heart. A healthy heart can be attained in a variety,of ways that ...
... PORTLAND, Ore. An Oregon Health & Science University Cancer ... the ability to predict if a mans prostate cancer is ... In order to make this discovery, researchers examined prostate cancer ... cancer patients. The researchers found that men whose tumors showed ...
... course of the presidential nomination campaign, some candidates health ... the phrase socialized medicine has been used to attack ... poll by the Harvard Opinion Research Program at the ... finds that Americans are split on whether a socialized ...
... National Board, KNOXVILLE, Tenn., Feb. 14 ... of Stacy Goldsholl, MD, as an,officer of its ... Medicine, is serving her second consecutive term as ... the premier medical society that,represents hospitalists. Hospital medicine ...
... (Nasdaq: DATA ), a technology company focused ... today reported that it will be,presenting at the ... at the Ritz Carlton in Laguna Niguel, California, ... on Wednesday afternoon,February 20th at 2:30 P.M., Pacific ...
... researchers from Europe and North America were given important ... national boundaries at a two-day training course in Croydon, ... Foundation as part of its Pan-European Clinical Trials (ECT) ... trials with a specific focus on the Euramos trial ...
Cached Medicine News:Health News:Healthy Heart, Healthy Home 2Health News:OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:Stacy Goldsholl, MD, Re-elected to Board of Society of Hospital Medicine 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 3Health News:ESF's EMRC strengthens training course on clinical trials management 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: